Cargando…

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life

Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeppesen, P. B., Lund, P., Gottschalck, I. B., Nielsen, H. B., Holst, J. J., Mortensen, J., Poulsen, S. S., Quistorff, B., Mortensen, P. B.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706978/
https://www.ncbi.nlm.nih.gov/pubmed/19590736
http://dx.doi.org/10.1155/2009/425759
_version_ 1782169115850440704
author Jeppesen, P. B.
Lund, P.
Gottschalck, I. B.
Nielsen, H. B.
Holst, J. J.
Mortensen, J.
Poulsen, S. S.
Quistorff, B.
Mortensen, P. B.
author_facet Jeppesen, P. B.
Lund, P.
Gottschalck, I. B.
Nielsen, H. B.
Holst, J. J.
Mortensen, J.
Poulsen, S. S.
Quistorff, B.
Mortensen, P. B.
author_sort Jeppesen, P. B.
collection PubMed
description Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two years of subcutaneous GLP-2 treatment, 400 microgram TID, intermitted by an 8-week washout period. Methods. Safety and compliance was evaluated during the admissions. The Sickness Impact Profile (SIP), Short Form 36 (SF 36), and Inflammatory Bowel Disease Questionnaire (IBDQ) evaluated quality of life. Results. The predominant adverse event was transient abdominal discomfort in 5 of 11 patients, but in 2, both suffering from Crohns disease, it progressed to abdominal pain and led to discontinuation of GLP-2 treatment. One had a fibrostenotic lesion electively resected at the jejuno-ascendo-anastomosis. The investigator excluded a patient due to unreliable feedback. Stoma nipple enlargement was seen in all 9 jejunostomy patients. Reported GLP-2 compliance was excellent (>93%). GLP-2 improved the overall quality of life VAS-score (4.1 ± 2.8 cm versus 6.0 ± 2.4 cm, P < .01), the overall SIP score (10.3 ± 8.9% versus 6.2 ± 9.5%, P < .001), the mental component of the SF-36 (45 ± 13% versus 53 ± 11%, P < .05), and the overall IBDQ score (5.1 ± 0.9 versus 5.4 ± 0.9, P < .007) in the 8 patients completing the study. Conclusions. Long-term treatment with GLP-2 is feasible in SBS patients, although caution must be exercised in patients with a history of abdominal pain. Although conclusions cannot be made in a noncontrolled trial, the high reported compliance might reflect a high treatment satisfaction, where the clinical benefits of GLP-2 may outweigh the discomforts of injections.
format Text
id pubmed-2706978
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-27069782009-07-09 Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life Jeppesen, P. B. Lund, P. Gottschalck, I. B. Nielsen, H. B. Holst, J. J. Mortensen, J. Poulsen, S. S. Quistorff, B. Mortensen, P. B. Gastroenterol Res Pract Clinical Study Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two years of subcutaneous GLP-2 treatment, 400 microgram TID, intermitted by an 8-week washout period. Methods. Safety and compliance was evaluated during the admissions. The Sickness Impact Profile (SIP), Short Form 36 (SF 36), and Inflammatory Bowel Disease Questionnaire (IBDQ) evaluated quality of life. Results. The predominant adverse event was transient abdominal discomfort in 5 of 11 patients, but in 2, both suffering from Crohns disease, it progressed to abdominal pain and led to discontinuation of GLP-2 treatment. One had a fibrostenotic lesion electively resected at the jejuno-ascendo-anastomosis. The investigator excluded a patient due to unreliable feedback. Stoma nipple enlargement was seen in all 9 jejunostomy patients. Reported GLP-2 compliance was excellent (>93%). GLP-2 improved the overall quality of life VAS-score (4.1 ± 2.8 cm versus 6.0 ± 2.4 cm, P < .01), the overall SIP score (10.3 ± 8.9% versus 6.2 ± 9.5%, P < .001), the mental component of the SF-36 (45 ± 13% versus 53 ± 11%, P < .05), and the overall IBDQ score (5.1 ± 0.9 versus 5.4 ± 0.9, P < .007) in the 8 patients completing the study. Conclusions. Long-term treatment with GLP-2 is feasible in SBS patients, although caution must be exercised in patients with a history of abdominal pain. Although conclusions cannot be made in a noncontrolled trial, the high reported compliance might reflect a high treatment satisfaction, where the clinical benefits of GLP-2 may outweigh the discomforts of injections. Hindawi Publishing Corporation 2009 2009-07-05 /pmc/articles/PMC2706978/ /pubmed/19590736 http://dx.doi.org/10.1155/2009/425759 Text en Copyright © 2009 P. B. Jeppesen et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Jeppesen, P. B.
Lund, P.
Gottschalck, I. B.
Nielsen, H. B.
Holst, J. J.
Mortensen, J.
Poulsen, S. S.
Quistorff, B.
Mortensen, P. B.
Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
title Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
title_full Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
title_fullStr Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
title_full_unstemmed Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
title_short Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
title_sort short bowel patients treated for two years with glucagon-like peptide 2 (glp-2): compliance, safety, and effects on quality of life
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706978/
https://www.ncbi.nlm.nih.gov/pubmed/19590736
http://dx.doi.org/10.1155/2009/425759
work_keys_str_mv AT jeppesenpb shortbowelpatientstreatedfortwoyearswithglucagonlikepeptide2glp2compliancesafetyandeffectsonqualityoflife
AT lundp shortbowelpatientstreatedfortwoyearswithglucagonlikepeptide2glp2compliancesafetyandeffectsonqualityoflife
AT gottschalckib shortbowelpatientstreatedfortwoyearswithglucagonlikepeptide2glp2compliancesafetyandeffectsonqualityoflife
AT nielsenhb shortbowelpatientstreatedfortwoyearswithglucagonlikepeptide2glp2compliancesafetyandeffectsonqualityoflife
AT holstjj shortbowelpatientstreatedfortwoyearswithglucagonlikepeptide2glp2compliancesafetyandeffectsonqualityoflife
AT mortensenj shortbowelpatientstreatedfortwoyearswithglucagonlikepeptide2glp2compliancesafetyandeffectsonqualityoflife
AT poulsenss shortbowelpatientstreatedfortwoyearswithglucagonlikepeptide2glp2compliancesafetyandeffectsonqualityoflife
AT quistorffb shortbowelpatientstreatedfortwoyearswithglucagonlikepeptide2glp2compliancesafetyandeffectsonqualityoflife
AT mortensenpb shortbowelpatientstreatedfortwoyearswithglucagonlikepeptide2glp2compliancesafetyandeffectsonqualityoflife